title: Emerging gene-based prognostic tools in early breast cancer: First steps to personalised medicine.
abstract: Breast cancer remains a major cause of neoplastic disease in much of the developed world. The majority of cases are diagnosed with oestrogen receptor (ER)-positive and human epidermal growth factor receptor-2 negative invasive ductal carcinoma and are treated predominantly by surgery which includes sentinel node biopsy and adjuvant endocrine therapy ± adjuvant radiotherapy. It is believed that an indeterminate subset of the patient population is needlessly incurring chemotherapy related morbidity without attaining any increase in survival due to therapy. Furthermore in the era of extended adjuvant endocrine therapy it is important to identify those patients who can be safely treated with 5 years rather than 10 years of endocrine therapy thus optimising the benefit-risk balance. This perception has propelled the development of more personalised prognostic tools for newly diagnosed cases of ER-positive breast cancer. In this article, we shall review the evidence regarding the currently available gene assays for human breast cancer.
authors.affiliation: Umar Wazir, Kefah Mokbel, The London Breast Institute, Princess Grace Hospital, London W1U 5NY, United Kingdom.
authors.forename: Umar
authors.initials: U
authors.lastname: Wazir
authors.affiliation: Umar Wazir, Kefah Mokbel, The London Breast Institute, Princess Grace Hospital, London W1U 5NY, United Kingdom.
authors.forename: Kefah
authors.initials: K
authors.lastname: Mokbel
keywords: Breast cancer; Personalised medicine; Polymerase chain reaction; Prognosis